Decision for funding in the neurology, immunosuppression, diabetes and anti-thrombotic therapy areas

PHARMAC

11 July 2019 - PHARMAC is pleased to announce the approval of a decision relating to medicines in the neurology, immunosuppression, diabetes and anti-thrombotic areas.

In summary, this will result in the following changes from 1 August 2019:

  • Rituximab (Mabthera) access will be widened to include treatment of neuromyelitis optica spectrum disorders and severe refractory myasthenia gravis.
  • Bevacizumab and human papillomavirus (HPV) vaccine (Gardasil 9) will be funded in DHB hospitals for treatment of recurrent respiratory papillomatosis.
  • Adalimumab (Humira) access will be widened to include treatment of Behçet's disease.
  • The quantity of funded insulin needles permitted per prescription will be increased.
  • Intravenous aspirin (lysine acetyl salicylate) will be funded in DHB hospitals for use during acute interventional cardiology and neuro-radiology procedures.

Read PHARMAC press release

Michael Wonder

Posted by:

Michael Wonder